Singapore's ASLAN Licenses Gastric Cancer Compound From Array; Will Bring To POC And Find Partner
This article was originally published in PharmAsia News
Executive Summary
Singapore's ASLAN Pharmaceuticals Pte Ltd. has inked a licensing deal with Colorado-based Array BioPharma Inc. to develop Array's oral HER2/EGFR inhibitor ARRY-543, currently entering Phase II for solid tumors
You may also be interested in...
ASLAN Gets Global Rights To Almirall RA Candidate, Third Deal In Less Than A Year For Singapore Startup
ASLAN Pharmaceuticals branches out from oncology for its third compound, but the formula is the same: in-license for Asia and find a CRO.
Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds
Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds